HANNOVER, Germany and SAN DIEGO, USA, December 01, 2021 / B3C newswire / -- Implandata Ophthalmic Products, a digital eye care company based in Germany and USA, was awarded 1st place at the Healthcare Innovation World Cup at MEDICA, the world’s largest medical trade fair. In an intense competition, with 300 healthtech companies from 60 countries, Implandata and its disruptive EYEMATE™ system were recognized by the expert jury as the top digital health solution based on the level of innovation, go-to-market-approach, commercial potential and sustainability.
Max Ostermeier, CEO and founder of the company states: “The Implandata team is very excited and proud to win this prestigious award. It confirms the high degree of innovation of our EYEMATE system, and the huge market opportunity it addresses.”
Dominick Arena, Chairman of the company says: “Implandata is currently preparing the European market launch of the EYEMATE system and has started the US market FDA approval process. The company will build a strong business foundation on the sales of EYEMATE biosensors and recurring revenues for remote patient monitoring and therapy guidance services.”
Investors value the MEDICA Innovation World Cup, a premier venue for companies that are transforming healthcare. Remote patient monitoring and telehealth are a key focus, as they are powering the transformation of chronic disease management, including the $6B glaucoma care market.
For high resolution please click the image.
About Glaucoma – the leading cause of irreversible, debilitating vision loss worldwide
80 million people with the chronic eye disease glaucoma suffer the risk of permanently losing vision, eventually going blind. Current practice (typically 4 office visits/year) is insufficient to prevent vision loss for many patients. Glaucoma status between visits is unknown. Though doctors have many treatment options, delayed detection of disease progression delays therapy adjustment and results in further loss of eyesight.
About the EYEMATE™ System
EYEMATE is the world’s only CE-marked, clinically-validated system for remote glaucoma care. Implandata’s patented biosensors and cloud-based, AI-system alert patients and their eye doctor in real-time of uncontrolled glaucoma. When the disease progresses, EYEMATE enables the therapy to be adjusted immediately – before the patient loses further vision
About Implandata Ophthalmic Products
Implandata, based in Germany/USA, is a digital health & medical device company dedicated to improving the lives of millions of people with glaucoma. Breakthroughs in biosensing, telemetry and data analytics led to the EYEMATE system. The CE-marked EYEMATE system is in use at leading eye centers in Europe. In the US market, EYEMATE has obtained the FDA “Breakthrough Device Designation”. In China, EYEMATE is ready to start the NMPA approval process.
Contact
Implandata Ophthalmic Products
Max Ostermeier, CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.implandata.com
Keywords: Humans: Awards and Prizes; Glaucoma; Vision Disorders; Intraocular Pressures; Pressure, Intraocular; Monitoring, Physiological; Eye Diseases; Disease Progression; Patient Monitoring; Remote Patient Monitoring; Digital Health; Telemedicine; Biosensors; Biosensing Techniques; AI, Deep Learning; Ophthalmology; Remote Monitoring; Telemedicine; Breakthrough Device Designation; Telehealth; Medica; FDA; CE Mark; NMPA; Germany; North America
Published by B3C newswire